Dr. Brian Wainger, Massachusetts General Hospital, will provide a brief update on the clinical trial. ALS Patient and Advocate, Stephen Winthrop and Dr. Wainger will discuss the trial from the ALS patient and research perspectives.
In partnership with The ALS Association, NEALS offers live webinars for people with ALS, caregivers and the broader ALS community. Experts explain the scientific rationale and design of current ALS research. Our webinars also offer participants the opportunity to ask questions directly of the experts running clinical trials and conducting research activities.
Speaker: Michael Weiss, MD, University of Washington Medical Center
Overexcitation (hyperexcitability) of motor neurons appears to be an early process in ALS and could lead to cell death. The objective of this phase II study is to determine the effects of mexiletine, a cardiac anti-arrhythmic medication, on cortical hyperexcitability in ALS subjects using transcranial magnetic stimulation, a device which employs magnetic fields to target the motor cortex of the brain to determine their level of excitation, and on peripheral nerve excitability using threshold tracking, a technique that stimulates the nerves with low levels of electricity. Reduction of hyperexcitability may suggest that a larger and longer phase III study is warranted to determine whether mexiletine slows progression of the disease. Join us to hear more about this study!
Speakers: Wendy E. Kaye, PhD, McKing Consulting Corporation and Paul Mehta, MD, National ALS Registry
The National ALS Registry does more than just count ALS cases. Learn how the Registry promotes and advances ALS research by connecting patients with researchers for clinical trials and studies, funding etiological research, and facilitating the availability of biological specimens collected by the newly launched National ALS Biorepository where patients can donate their specimens to advance ALS research.
Speaker: Sherry Kolodziejczak, MS, OTR/L, Crestwood Medical Center
This presentation will review the documentation requirements for power wheelchair evaluation. The Medicare Power Wheelchair form will be reviewed in a line-by-line basis teaching the required documentation requirements. Required documentation areas also discussed include the Physician Face-to-Face Exam, the 7 element order, the therapist Specialty Examination, and the detailed product description/letter of medical necessity. When proper submission of the power wheelchair evaluation documentation follows the 9 step Algorithm, approval and delivery of power wheelchair to the client is assured.